Accessibility StatementSkip Navigation NEW YORK, Oct. 2, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, both dates inclusive (the "Class Period"), of the important October 6, 2025 lead plaintiff deadline. So What: If you purchased Altimmune securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the “Class Period”), of the important October 6, 2025 lead plaintiff deadline. SO WHAT: If you purchased Altimmune securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Altimmune class acti ...

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the “Class Period”), of the important October 6, 2025 lead plaintiff deadline. SO WHAT: If you purchased Altimmune securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Altimmune class acti ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, of the October 6, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Altimmune, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - To join the class action, investors can submit a form or contact the law firm for more information [2][5] - The lawsuit claims that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, failing to meet a key statistical significance marker for fibrosis reduction [4] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, of the October 6, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Altimmune, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - To join the class action, investors can submit a form online or contact the law firm directly for more information [2][5] - The lawsuit claims that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, failing to meet a key statistical significance marker related to fibrosis reduction [4] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, about the October 6, 2025, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - A class action lawsuit has been filed against Altimmune, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2]. - To join the class action, investors can submit a form online or contact the law firm directly for more information [2][5]. - The lawsuit claims that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, failing to meet a key statistical significance marker for fibrosis reduction [4]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [3]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [3]. Group 3: Case Specifics - The lawsuit alleges that Altimmune created a false impression regarding the reliability of its trial results, which ultimately led to investor damages when the true results were revealed [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, about the October 6, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Altimmune, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - To participate in the class action, investors can submit a form or contact the law firm for more information [2][5] - The lawsuit claims that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, leading to investor damages when the true results were revealed [4] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [3] - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [3] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, of the October 6, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Altimmune, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - To participate in the class action, investors can submit a form or contact the law firm for more information [2][5] - The lawsuit claims that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, leading to investor damages when the true results were revealed [4] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [3] - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [3]

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. on behalf of shareholders who purchased securities between August 10, 2023, and June 25, 2025, alleging that the company misrepresented the results of its IMPACT Phase 2b MASH trial [1][4]. Group 1: Lawsuit Details - The lawsuit claims that Altimmune created a false impression regarding the reliability of information related to the IMPACT Phase 2b MASH trial results, specifically failing to meet a key statistical significance marker for fibrosis reduction [4]. - Altimmune allegedly inflated expectations for positive results while concealing adverse data from the placebo group, which negatively impacted the topline results [4]. - When the true results were disclosed, investors reportedly suffered damages due to the misleading information provided by Altimmune [4]. Group 2: Participation Information - Shareholders who purchased Altimmune securities may be entitled to compensation through a contingency fee arrangement, meaning no out-of-pocket fees or costs are required [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm for more information [3][5]. - A lead plaintiff must file a motion with the court by October 6, 2025, to represent other class members in the litigation [1][3].

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for allegedly misleading investors regarding the results of its IMPACT Phase 2b MASH trial, which did not meet key statistical significance markers [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Altimmune securities between August 10, 2023, and June 25, 2025 [1]. - The lawsuit claims that Altimmune created a false impression of reliable information regarding trial results, while concealing negative data that would impact the topline results [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and has a strong track record in recovering funds for investors [4]. - Investors wishing to serve as lead plaintiff must file their motion by October 6, 2025 [1][3]. Group 3: Trial Results - Altimmune's IMPACT Phase 2b MASH trial failed to achieve statistical significance for the primary endpoint related to fibrosis reduction, contrary to the company's previous claims [5]. - The lawsuit alleges that the company concealed higher responses in the placebo group, which negatively affected the trial's topline results [5].